An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant
- PMID: 7666543
- PMCID: PMC189542
- DOI: 10.1128/JVI.69.10.6424-6429.1995
An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant
Abstract
The human immunodeficiency virus type 1 strain MN (HIV-1MN) principal neutralizing determinant (PND, V3 loop) was introduced into infectious molecular clones HIV-2KR and simian immunodeficiency virus mm239 (SIVmm239) by hybridization PCR, replacing the corresponding HIV-2 or SIV envelope cysteine loops with the HIV-1 coding sequence. The HIV-2 chimera (HIV-2KR-MNV3) was found to be capable of infecting a number of T-cell lymphoblastic cell lines as well as primary peripheral blood mononuclear cells. In contrast, the SIV chimera (SIV239MNV3) was not replication competent. Envelope produced by HIV-2KR-MNV3 but not the parental HIV-2KR was recognized by V3-specific and HIV-1-specific polyclonal antisera in radioimmunoprecipitation assays. HIV-2-specific antisera recognized both the chimeric and parental virus but not HIV-1MN. The chimeric HIV-2KR-MNV3 virus proved to be exquisitely susceptible to neutralization by HIV-1-specific and V3-specific antisera, suggesting the potential for use in animal models designed to test HIV-1 vaccine candidates which target the PND.
Similar articles
-
Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.J Virol. 1995 Oct;69(10):6342-51. doi: 10.1128/JVI.69.10.6342-6351.1995. J Virol. 1995. PMID: 7666535 Free PMC article.
-
Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10527-31. doi: 10.1073/pnas.89.21.10527. Proc Natl Acad Sci U S A. 1992. PMID: 1438241 Free PMC article.
-
An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.J Virol. 1996 May;70(5):3198-206. doi: 10.1128/JVI.70.5.3198-3206.1996. J Virol. 1996. PMID: 8627800 Free PMC article.
-
Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.Curr Top Microbiol Immunol. 1994;188:185-219. doi: 10.1007/978-3-642-78536-8_11. Curr Top Microbiol Immunol. 1994. PMID: 7523031 Review.
-
SIV/HIV recombinants and their use in studying biological properties.AIDS Res Hum Retroviruses. 1992 Mar;8(3):403-9. doi: 10.1089/aid.1992.8.403. AIDS Res Hum Retroviruses. 1992. PMID: 1571199 Review.
Cited by
-
Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.J Virol. 2002 Nov;76(21):10627-36. doi: 10.1128/jvi.76.21.10627-10636.2002. J Virol. 2002. PMID: 12368305 Free PMC article.
-
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19. J Virol. 2009. PMID: 19019969 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases